SCHEMBL5682007

SCHEMBL5682007

Cc1nn([C@H](N)C(C)OC(=O)/C=C/C(=O)OC(C)[C@@H](N)n2nc(C)c3cc(F)c(Cl)cc32)c2cc(Cl)c(F)cc12

nearest known ligand 0.32

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 2/20 0.32
ALDH1A1 P00352 2/20 0.31
HTR2A P28223 2/20 0.31
HTR2C P28335 2/20 0.31
CYP1A2 P05177 1/20 0.31
CYP3A4 P08684 1/20 0.31
CYP2C9 P11712 1/20 0.31
HTR2B P41595 1/20 0.31
LMNA P02545 1/20 0.30
KMT2A Q03164 1/20 0.30
L3MBTL1 Q9Y468 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5682170 0.91
SCHEMBL5678015 0.77 SMN1; SMN2 (0.46) ALDH1A1CYP1A2LMNAKMT2AL3MBTL1
SCHEMBL5678098 0.77 DYRK1A (0.38) ALDH1A1HTR2AHTR2CHTR2B
SCHEMBL7778389 0.74 SLC22A12 (0.35) PTGS2ALDH1A1LMNAKMT2AL3MBTL1
SCHEMBL905952 0.74 HTR2A (0.35) PTGS2HTR2AHTR2CCYP1A2CYP3A4
SCHEMBL5678034 0.71 PTGDR2 (0.34) HTR2AHTR2C
Fumaric Acid SCHEMBL5682016 0.70 HTR2A (0.41) HTR2AHTR2CCYP1A2CYP3A4CYP2C9
Fumaric Acid SCHEMBL5682001 0.70 HTR2A (0.41) HTR2AHTR2CCYP1A2CYP3A4CYP2C9
SCHEMBL5682015 0.67 SLC22A12 (0.32) ALDH1A1HTR2AHTR2CHTR2BKMT2A
SCHEMBL7779507 0.67 SLC22A12 (0.32) ALDH1A1HTR2AHTR2CHTR2BKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1129078-B1 INDAZOLE DERIVATIVES WITH 5-HT2 RECEPTOR ACTIVITY VERNALIS RES LTD (GB) 2006-03-15 EP disclosed
US-6552062-B1 For therapy of central nervous system disorders; damage to the central nervous system; cardiovascular disorders; gastrointestinal disorders; diabetes insipidus, and sleep apnea, and obesity VERNALIS RESEARCH LIMITED (GB) 2003-04-22 US disclosed